NEW YORK and LONDON, April 24, 2017 -Interim Phase 2 PNH data demonstrate positive response with Coversin™ -Phase 3 PNH program expected to commence in …
Akari Therapeutics to Present at the Jefferies Complement Symposium
NEW YORK and LONDON, April 3, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. …
[Read more...] about Akari Therapeutics to Present at the Jefferies Complement Symposium
Akari Therapeutics Announces FDA Fast Track Designation For Coversin
NEW YORK and LONDON, March 30th, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that …
[Read more...] about Akari Therapeutics Announces FDA Fast Track Designation For Coversin
Akari Therapeutics Announces R&D Day on April 24, 2017
NEW YORK and LONDON, March 17th, 2017 -- Presentation to Include New Coversin Phase II Data in PNH and Latest Data on Pipeline – Akari Therapeutics …
[Read more...] about Akari Therapeutics Announces R&D Day on April 24, 2017
Akari Therapeutics to Present at the 29th Annual ROTH Conference
NEW YORK and LONDON, March 7th, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that …
[Read more...] about Akari Therapeutics to Present at the 29th Annual ROTH Conference
